About this trial
Sex and gender are important factors that influence treatment response in PsA. The goal of this multi-centre observational study is to understand how sex and gender influence response to advanced therapies in psoriatic arthritis (PsA). The investigators hope to discover biological and socio-cultural mechanisms that explain the differences in treatment response between men and women with PsA.
The study investigators plan to recruit patients from approximately 30 sites across the world. Men and women with active PsA will be assessed before and after they start advanced therapies and information will be collected about sex- and gender-related factors through questionnaires and physical examination. Physicians will assess the patient response to treatment. The investigators will compare the response to treatment in men and women and assess what biological and socio-cultural factors contribute to differences in treatment response.
Eligibility criteria
Qualifiers
Rheumatologist confirmed diagnosis of PsA according to CASPAR criteria
Age ≥18 years
Active PsA with any of the following manifestations detected on physical examination: peripheral arthritis, dactylitis, and enthesitis. The patient may have axial involvement in addition to the peripheral manifestations of PsA
Plan to start treatment with advanced therapies for peripheral musculoskeletal manifestations of PsA
Disqualifiers
Unable to read or write
Unable to sign informed consent
Cannot return for a follow up visit
The drug is given for another indication and not for active PsA (e.g. psoriasis, IBD)
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
Women's College Hospital
Lead sponsor
University of Toronto
Sponsor institution